Mark Jeffrey DeLong - 12 Aug 2024 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Signature
/s/ David Watson, attorney-in-fact for Mark DeLong
Issuer symbol
APLS
Transactions as of
12 Aug 2024
Net transactions value
+$72,034
Form type
4
Filing time
13 Aug 2024, 16:13:09 UTC
Previous filing
19 Mar 2024
Next filing
14 Jan 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Options Exercise $72,034 +5,201 +9.4% $13.85 60,395 12 Aug 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -5,201 -26% $0.000000 14,799 12 Aug 2024 Common Stock 5,201 $13.85 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This includes 501 shares from 04/30/2024 ESPP purchase.
F2 This option was granted on February 8, 2019 and fully vested.